Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medicines Company, a US-based pharmaceutical company, has announced that the marketing authorization application for Cleviprex has been accepted for review in the European Union for the reduction of blood pressure when rapid and predictable control is desired.
Subscribe to our email newsletter
The marketing authorization application (MAA) for Cleviprex was submitted via the decentralized procedure, with the UK acting as the reference member state.
Concerned member states participating in the review are Austria, Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and Sweden. The Medicines Company anticipates making Cleviprex available in the European Union in 2010.
John Kelley, president and COO of The Medicines Company, said: “This regulatory submission is another step in our corporate strategy to build a leading global critical care medicines business that offers valuable, safe and effective medicines. If approved, Cleviprex will provide European physicians with an effective tool that could advance the management of blood pressure in the surgical and critical care settings.”